Category:
Active Pharmaceutical Ingredients
CAS NO:
1
Standard:
USP;BP,
These proteasome inhibitors treat hematologic malignancies via irreversible or reversible 20S proteasome blockade. Bortezomib (CAS: 179324-69-7, C25H37N7O4P), Carfilzomib (CAS: 863222-77-7, C35H52N6O7), and Ixazomib (CAS: 1139992-08-3, C24H32N6O4) are synthesized using advanced peptide coupling.
Strict cold chain storage at -20°C is mandatory. Clinical use requires monitoring for neuropathy, thrombocytopenia, and cardiotoxicity. Personnel must utilize PPE to prevent dermal exposure during handling.